Treatment
- abiraterone
- anastrozole
- bicalutamide
- capecitabine
- CAPOX
- carboplatin
- cetuximab
- cisplatin
- crizotinib
- dacarbazine
- docetaxel
- doxorubicin
- epirubicin
- erlotinib
- everolimus
- exemestane
- fluorouracil
- flutamide
- FOLFOX
- FOLFIRI
- fulvestrant
- gefitinib
- gemcitabine
- goserelin
- imatinib
- irinotecan
- lapatinib
- letrozole
- leuprolide
- liposomal doxorubicin
- megestrol acetate
- nab-paclitaxel
- oxaliplatin
- paclitaxel
- panitumumab
- pemetrexed
- pertuzumab
- sorafenib
- sunitinib
- tamoxifen
- temozolomide
- temsirolimus
- topotecan
- toremifene
- trastuzumab
- vemurafenib
fulvestrant
Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive manner with affinity comparable to that of estradiol. It also downregulates the ER protein in breast cancer. Fulvestrant is indicated* for treatment of hormone-receptor-positive breast cancer in postmenopausal women.
*Please refer to full prescribing information/package insert for precise indications.
